10 percent urea cream superior to new ointment for hand-foot syndrome
the ONA take:
According to a new study published online ahead of print in the Journal of Clinical Oncology, researchers have found that 10% urea cream is superior to a newly introduced ointment containing various antioxidants at preventing hand-foot syndrome during the first 6 weeks of treatment with capecitabine for gastrointestinal or breast cancer.
For the phase III trial, researchers enrolled 152 patients with gastrointestinal tumors or breast cancer who were treated with oral capecitabine. Participants were randomly assigned to receive urea cream or the new ointment, which has been available on the German market since 2011.
Results showed that 30.9% of patients who received the new ointment experienced hand-foot syndrome compared with 22.4% in the urea cream group (OR = 2.37; P=0.02).
Researchers found that time to any-grade hand-foot syndrome was significantly longer in the urea cream arm than the new ointment arm (P=0.03). The study also demonstrated that skin-related quality of life was significantly worse in the new ointment group than the urea group at the end of study treatment.
10% urea cream is superior to a newly introduced ointment containing various antioxidants at preventing hand-foot syndrome.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|